(HLVX) Hillevax - Ratings and Ratios
Norovirus Vaccine
Description: HLVX Hillevax
Hillevax Inc (NASDAQ:HLVX) is a US-based biotechnology company. The stock is currently trading at $2.06, with a market capitalization of $103.51 million. The companys financials indicate a significant loss, reflected in the negative Return on Equity (ROE) of -44.61%. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, suggests that the company is not profitable.
To evaluate the companys prospects, key drivers to consider include the progress of its pipeline assets, particularly any upcoming clinical trials or potential FDA approvals. The biotechnology industry is heavily influenced by regulatory decisions, and a successful approval can significantly impact a companys valuation. Additionally, the companys cash burn rate and runway will be crucial in determining its ability to continue operations and invest in future growth initiatives.
From a trading perspective, HLVX has a relatively low Average True Range (ATR) of 0.02, indicating limited price volatility. The stocks beta of 0.766 suggests that it is less volatile than the overall market. Key levels to monitor include the 52-week high of $2.17 and low of $1.39, as well as the Simple Moving Averages (SMA) of 20, 50, and 200 days, which currently stand at $2.08, $2.04, and $1.90, respectively.
To assess the potential for future growth, investors should focus on key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses as a percentage of revenue, and the companys cash and cash equivalents. A thorough analysis of these metrics will help determine whether HLVX is on track to achieve profitability and create value for shareholders.
HLVX Stock Overview
| Market Cap in USD | 104m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-04-29 |
HLVX Stock Ratings
| Growth Rating | -29.5% |
| Fundamental | 32.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.70% |
| Analyst Rating | 3.0 of 5 |
HLVX Dividends
Currently no dividends paidHLVX Growth Ratios
| Growth Correlation 3m | 37.2% |
| Growth Correlation 12m | 53% |
| Growth Correlation 5y | -67.3% |
| CAGR 5y | -53.45% |
| CAGR/Max DD 3y | -0.57 |
| CAGR/Mean DD 3y | -1.39 |
| Sharpe Ratio 12m | -0.12 |
| Alpha | 0.00 |
| Beta | 0.997 |
| Volatility | 42.36% |
| Current Volume | 2800.2k |
| Average Volume 20d | 743.5k |
| Stop Loss | 2 (-4.3%) |
| Signal | -0.82 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-71.1m TTM) > 0 and > 6% of Revenue (6% = 5.05m TTM) |
| FCFTA -0.62 (>2.0%) and ΔFCFTA -27.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 185.4% (prev 7101 %; Δ -6915 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.34 (>3.0%) and CFO -59.5m > Net Income -71.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 26.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (50.1m) change vs 12m ago 1.90% (target <= -2.0% for YES) |
| Gross Margin -84.44% (prev -0.52%; Δ -83.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 37.27% (prev 1.03%; Δ 36.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -37.37 (EBITDA TTM -66.6m / Interest Expense TTM 1.85m) >= 6 (WARN >= 3) |
Altman Z'' -27.65
| (A) 0.89 = (Total Current Assets 162.2m - Total Current Liabilities 6.15m) / Total Assets 174.9m |
| (B) -3.13 = Retained Earnings (Balance) -547.2m / Total Assets 174.9m |
| warn (B) unusual magnitude: -3.13 — check mapping/units |
| (C) -0.31 = EBIT TTM -69.2m / Avg Total Assets 225.9m |
| (D) -20.24 = Book Value of Equity -548.4m / Total Liabilities 27.1m |
| Total Rating: -27.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.13
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda -0.37 = -2.50 |
| 6. ROIC - WACC (= -52.43)% = -12.50 |
| 7. RoE -44.61% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 39.48% = 1.97 |
What is the price of HLVX shares?
Over the past week, the price has changed by -0.95%, over one month by +1.46%, over three months by +12.97% and over the past year by +15.47%.
Is Hillevax a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLVX is around 1.54 USD . This means that HLVX is currently overvalued and has a potential downside of -26.32%.
Is HLVX a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HLVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2 | -4.3% |
| Analysts Target Price | 2 | -4.3% |
| ValueRay Target Price | 1.7 | -17.7% |
Last update: 2025-09-04 04:39
HLVX Fundamental Data Overview
CCE Cash And Equivalents = 159.5m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -71.1m + Cost of Revenue 155.3m = 84.2m USD
P/B = 0.7053
Beta = 0.766
Revenue TTM = 84.2m USD
EBIT TTM = -69.2m USD
EBITDA TTM = -66.6m USD
Long Term Debt = 20.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.63m USD (from shortTermDebt, last quarter)
Debt = 24.6m USD (Calculated: Short Term 3.63m + Long Term 20.9m)
Net Debt = -35.1m USD (from netDebt column, last quarter)
Enterprise Value = -30.7m USD (104.3m + Debt 24.6m - CCE 159.5m)
Interest Coverage Ratio = -37.37 (Ebit TTM -69.2m / Interest Expense TTM 1.85m)
FCF Yield = -356.0% (FCF TTM -109.3m / Enterprise Value -30.7m)
FCF Margin = -129.8% (FCF TTM -109.3m / Revenue TTM 84.2m)
Net Margin = -84.44% (Net Income TTM -71.1m / Revenue TTM 84.2m)
Gross Margin = -84.44% ((Revenue TTM 84.2m - Cost of Revenue TTM 155.3m) / Revenue TTM)
Tobins Q-Ratio = 0.06 (Enterprise Value -30.7m / Book Value Of Equity -548.4m)
Interest Expense / Debt = 7.54% (Interest Expense 1.85m / Debt 24.6m)
Taxrate = 21.0% (US default)
NOPAT = -69.2m (EBIT -69.2m, no tax applied on loss)
Current Ratio = 26.39 (Total Current Assets 162.2m / Total Current Liabilities 6.15m)
Debt / Equity = 0.17 (Debt 24.6m / last Quarter total Stockholder Equity 147.8m)
Debt / EBITDA = -0.37 (Net Debt -35.1m / EBITDA -66.6m)
Debt / FCF = -0.22 (Debt 24.6m / FCF TTM -109.3m)
Total Stockholder Equity = 159.4m (last 4 quarters mean)
RoA = -40.65% (Net Income -71.1m, Total Assets 174.9m )
RoE = -44.61% (Net Income TTM -71.1m / Total Stockholder Equity 159.4m)
RoCE = -38.40% (Ebit -69.2m / (Equity 159.4m + L.T.Debt 20.9m))
RoIC = -43.45% (NOPAT -69.2m / Invested Capital 159.4m)
WACC = 8.98% (E(104.3m)/V(128.8m) * Re(9.69%)) + (D(24.6m)/V(128.8m) * Rd(7.54%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.72%
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -109.3m)
EPS Correlation: 39.48 | EPS CAGR: 12.22% | SUE: 0.31 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for HLVX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle